Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus chemoradiotherapy versus chemoradiotherapy for muscle-invasive bladder cancer
ISRCTN43698103Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Jun 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
A Phase 2 trial of durvalumab in muscle-invasive bladder cancer (MIBC), sponsored by University of Birmingham. Started Jun 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on ISRCTN43698103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43698103.